Please assess the completion status of the following clinical trial:

Trial Title: [18F]SF12051 for Imaging the 18-kDa Translocator Protein (TSPO) in Brain and Whole Body of Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~To be eligible to participate in this study, an individual must meet all of the following criteria:~* Aged 18 years or older.~* Healthy based on medical history, physical examination, and laboratory testing.~* Able to provide informed consent.~* Willing and able to complete all study procedures.~* Have been screened for TSPO genotype under 01-M-0254 The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Participants.~* Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists\*.~* Agree to adhere to the lifestyle considerations~  * Does not apply to Phase 1 and 3 participants as they will not have an arterial line.~EXCLUSION CRITERIA:~An individual who meets any of the following criteria will be excluded from participation in this study:~* Clinically significant abnormalities on EKG or laboratory testing. This includes CBC; acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen); hepatic panel (alkaline phosphatase, ALT, AST, bilirubin total, and bilirubin direct); mineral panel (albumin, calcium, magnesium, phosphorus); prothrombin and partial prothrombin tests.~* Participants should not have taken NSAIDs or willow bark tea for two weeks prior to the PET scan.~* Any current Axis I diagnosis.~* Positive test for HIV.~* Unable to have an MRI scan\*.~* History of neurologic illness or injury with the potential to affect study data interpretation.~* History of seizures, other than in childhood and related to fever.~* Recent exposure to radiation (i.e., PET from other research) which when combined with this study would be above the allowable limits.~* Inability to lie flat on camera bed for at least two hours, including claustrophobia and weight greater than the maximum for the scanner (500 lbs).~* Pregnancy or breast feeding.~* Able to get pregnant but does not use birth control.~* Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use affects the function of daily life.~* Unable to travel to NIH.~* National Institute of Mental Health (NIMH) staff or an NIH employee who is a subordinate/relative/co-worker of the investigators.~  * Phase 1 and 3 participants will not get an MRI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- High affinity binder (HAB) Translocator Protein (TSPO) genotype (Type: EXPERIMENTAL): Healthy participants with HAB TSPO genotype receive 18F-SF12051 intravenously followed by whole body or brain positron emission tomography (PET) scan. Participants were randomized to either phase 1, 2, or 3. Phases 1 \& 3 had whole body PET scan and phase 2 had brain PET scan.
- Low affinity binder (LAB) Translocator Protein (TSPO) genotype (Type: EXPERIMENTAL): Healthy participants with LAB TSPO genotype receive 18F-SF12051 intravenously followed by whole body or brain positron emission tomography (PET) scan. Participants were randomized to either phase 1, 2, or 3. Phases 1 \& 3 had whole body PET scan and phase 2 had brain PET scan.
- Mixed affinity binder (MAB) Translocator Protein (TSPO) genotype (Type: EXPERIMENTAL): Healthy participants with MAB TSPO genotype receive 18F-SF12051 intravenously followed by whole body or brain positron emission tomography (PET) scan. Participants were randomized to either phase 1, 2, or 3. Phases 1 \& 3 had whole body PET scan and phase 2 had brain PET scan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy